Handok Pharmaceuticals said it obtained the U.S. FDA approval to conduct a phase 2 clinical trial of ABL001 (CTX-009), an investigational anticancer treatment the Korean company is jointly developing with Compass Therapeutics.The FDA nod is meaningful particularly because the local phase 2 study of
Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve, a spray-type finasteride-based hair loss treatment, in Korea.The agreement will give Boryung exclusive sales rights for Finjuve in Korea.Finjuve, developed by Almirall, a global pharmaceutical company, is the
Hanmi Pharmaceutical and Celltrion said they would manufacture Lagevrio pills, low-cost version of Merck’s Covid-19 treatment molnupiravir, and supply them to 105 low- and-middle-income countries.The Medicines Patent Pool (MPP) has chosen 27 drugmakers, including the two Korean companies, to make an
Daewoong Pharmaceutical is actively engaging in the Covid-19 diagnostic kit business, saying it would roll out a rapid Covid-19 antigen test kit in Korea within the first half of this year.Pharmaceutical industry sources said on Friday that Daewoong was getting ready to launch a rapid Covid-19 testi
The U.S. FDA recently approved two JAK inhibitors – AbbVie’s Rinvoq (upadacitinib) and Pfizer’s Cibinqo (abrocitinib) – to treat atopic dermatitis on the condition that JAK inhibitors are given to those who have already received systemic therapy, including biologics.In Korea, the Ministry of Food an
“Until now, there was no way to prevent recurrence of breast cancer in high-risk HER2 early breast cancer patients who completed adjuvant antibody treatment. As there is no treatment to prevent brain metastasis, the market release of Nerlynx (ingredient: neratinib) could satisfy the unmet demand of
A set of unfavorable factors has engulfed biopharmaceutical companies to pull down their stock prices this month, extending last year’s downward trend.The market capitalization of biopharmaceutical stocks, which shrank by 70 trillion won ($58.8 billion) last year, has shed an additional 30 trillion
LG Chem said on Wednesday that the U.S. FDA authorized the company to conduct a phase 1 clinical trial of LG542019, a type-2 diabetes treatment candidate, which aims to reduce insulin resistance.The study will evaluate LC542019’s safety, tolerability, pharmacokinetics, and pharmacodynamics in 98 hea
The government is expected to allow functional health foods to be packaged in small amounts this year.Industry watchers are paying attention to whether JVM, a drug packaging subsidiary of Hanmi Science, will benefit from this and see sales increase in 2022.According to a report by EBEST Investment &
Multinational pharmaceutical companies continued to dominate Korea’s new drug market last year by winning nine out of 10 new drugs approvals.According to the new drug data at the Ministry of Food and Drug Safety, the regulator approved 48 new drugs -- 35 synthetic drugs and 13 biological drugs – dev
HLB Life Sciences said it has acquired all rights for an anticancer candidate substance developed by LSK NRDO, a local drug developer.The new anticancer substance features a mechanism that inhibits the proliferation of cancer cells by regulating signals involved in the cell cycle. The cell cycle ref
AstraZeneca’s anti-PD-L1 immunotherapy Imfinzi (ingredient: durvalumab) in combination with the standard chemotherapy lowered the risk of death by 20 percent in the treatment of biliary tract cancer, the company said.The results came from a global phase 3 trial, expanded from a phase 2 study led by
Two researchers at Seoul St. Mary's Hospital released a study result on Tuesday, which stresses the need for people with poor lung function to monitor their health, especially the possibility of diabetes closely.Diabetes mellitus is a systemic inflammatory disease in which high blood sugar persists
SK Bioscience has taken one more step towards commercializing a Korean-made Covid-19 vaccine.The company said it completed recruiting participants in a local phase 3 study of Covid-19 vaccine candidate GBP510.SK Bioscience is leading the race to make a homegrown Covid-19 vaccine among Korean vaccine
HLB Therapeutics said Tuesday that the U.S. Food and Drug Administration had approved the execution of an expanded access program (EAP) for its OKN-007, a treatment candidate for pediatric patients with disseminated intrinsic glioma (DIPG).The company has started administering the first dose of the
Daewoong Pharmaceutical is seeking to expand the indication of Easyef Oint., a wound ointment containing epidermal growth factor (EGF), to treat adverse skin reactions in cancer patients shown after the use of epidermal growth factor receptor (EGFR) inhibitors such as erlotinib.On Monday, the Minist
inno.N's gastroesophageal reflux disease (GERD) therapy, K-CAB, has become a blockbuster drug by surpassing annual sales of 100 billion won ($83.8 million) in just three years of its launch, the fastest among homegrown treatments.K-CAB’s outpatient prescription totaled 109.6 billion won last year, e
The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the first-line therapy for lung cancer has accelerated the company’s development of another oncology pipeline built from the backbone of Keytruda.On Friday, the Ministry of Food and Drug Safety authorized MSD to cond
GC said it has launched Pojinen cream, a compound treatment for recurrent herpes labialis.Herpes labialis is a disease caused by infection with the herpes virus, which remains in the body for life. The virus is usually dormant but becomes active when the immune system weakens, causing blisters, itch
Gemvax & KAEL said that it had received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with moderate to severe Alzheimer's disease.The company plans to conduct a multicenter, randomized, double-blind, placebo-